- Home
- EAF vs CRBU Comparison
EAF vs CRBU Comparison
Compare EAF & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | CRBU |
|---|---|---|
| Founded | 1886 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.6M | 166.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EAF | CRBU |
|---|---|---|
| Price | $5.89 | $1.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $11.75 | $10.75 |
| AVG Volume (30 Days) | 369.1K | ★ 2.6M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | N/A |
| Revenue This Year | $4.25 | $1.63 |
| Revenue Next Year | $12.49 | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $1.38 |
| 52 Week High | $20.32 | $3.53 |
Technical Indicators
Market Signals| Indicator | EAF | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 52.69 |
| Support Level | $4.92 | $1.73 |
| Resistance Level | $7.73 | $2.02 |
| Average True Range (ATR) | 0.68 | 0.13 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 32.12 | 57.27 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.